Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, Australia.
Pharmacogenet Genomics. 2011 Dec;21(12):902-5. doi: 10.1097/FPC.0b013e32834c5445.
Given the evidence from retrospective studies indicating that alcohol-dependent patients with homozygous or heterozygous A118G variant of the μ-opioid receptor, OPRM1, gene have significantly better outcomes when treated with naltrexone; this study examined this prospectively in 100 alcohol-dependent participants prescribed naltrexone for 12 weeks and offered six sessions of cognitive-behavioral therapy or intervention. Comparisons were made among OPRM1 genotypic groups on several outcome measures. Naltrexone treatment produced significant decreases in self-reported and objective indicators of alcohol use and craving from baseline (P<0.0001 and 0.017, respectively), particularly during the first 2 months of treatment, with 68% completing the study. However, there was no evidence of a significant association between OPRM1 A118G genotype and treatment success on any of the outcome measures. Therefore, while naltrexone was an effective treatment for alcohol dependence, the OPRM1 A118G genotype was not a predictor of success.
鉴于回顾性研究的证据表明，阿片μ受体（OPRM1）基因 A118G 变异纯合子或杂合子的酒精依赖患者在使用纳曲酮治疗时效果显著更好；本研究前瞻性地在 100 名接受纳曲酮治疗 12 周并接受 6 次认知行为治疗或干预的酒精依赖参与者中进行了检查。在几项结果测量指标上，对 OPRM1 基因型组进行了比较。纳曲酮治疗使自我报告和客观的酒精使用和渴望指标从基线显著下降（分别为 P<0.0001 和 0.017），特别是在治疗的前 2 个月，68%的患者完成了研究。然而，在任何结果测量指标上，OPRM1 A118G 基因型与治疗成功之间均无显著关联。因此，尽管纳曲酮是治疗酒精依赖的有效方法，但 OPRM1 A118G 基因型并不是成功的预测指标。
